United States · FDA National Drug Code directory
VYXEOS
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 68727-745_25abb1d8-f921-4aae-8240-1914cd80417a
- Product NDC
- 68727-745
- Form
- INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION
- Composition / generic term
- (daunorubicin and cytarabine) liposome
- Labeler
- Jazz Pharmaceuticals, Inc.
- Marketing category
- NDA
- Marketing start / end (source format)
- 20170803
- Source listing expiry
- 20271231
Source-listed ingredients
- CYTARABINE — 100 mg/20mL
- DAUNORUBICIN — 44 mg/20mL
These values do not establish equivalence or a dose recommendation.
Packages
- 20 mL in 1 VIAL (68727-745-01) · 68727-745-01
- 40 mL in 1 CARTON (68727-745-02) · 68727-745-02
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →